Biotech News
Related news
OTLKOutlook2026-05-15 20:05 EST
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
OTLKOutlook2026-06-16 12:02 EST
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD
LENZLenz Therapeutics Inc2026-08-04 20:05 EST
LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
LENZLenz Therapeutics Inc2026-05-04 12:00 EST
LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference
LCTXLineage Cell Therapeutics2026-07-30 12:00 EST
Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
LCTXLineage Cell Therapeutics2026-05-05 12:00 EST
Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026
BLTEBelite Bio2026-08-06 12:00 EST
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
OCGNOcugen2026-07-28 20:01 EST
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
BLTEBelite Bio2026-08-13 01:45 EST
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
KPRXKiora Pharmaceuticals2026-08-07 11:00 EST
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Outlook
Ophthalmic Bevacizumab Company Outlook Therapeutics develops and commercializes LYTENAVA, a bevacizumab formulation manufactured specifically for intravitreal administration in retinal diseases. The company is building a focused ophthalmology franchise around an approved alternative to repackaged bevacizumab originally produced for...
Recent company news
OTLKOutlook2026-09-11 11:00 EST
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
OTLKOutlook2026-09-10 13:10 EST
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
OTLKOutlook2026-08-27 20:05 EST
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
OTLKOutlook2026-08-27 13:01 EST
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
OTLKOutlook2026-08-14 11:15 EST
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
Stock data
- Close
- 0.65 USD
- Market cap
- 120.89M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States